Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04496947 · ClinicalTrials.gov registry record · NA
Pilot Study Evaluating the Impact of Stress Reduction on Atherosclerotic : Heart and Mind Study
A NA study of Stress and Inflammation, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04496947: Recruiting NA study of Stress and Inflammation, sponsored by Massachusetts General Hospital.
NCT04496947 is a NA study of Stress and Inflammation that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 786-participant average among 152 other Stress trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04496947, a NA study of Stress and Inflammation, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The plot study aims to evaluate the effect of 8 weeks of stress reducing intervention on atherosclerotic plaque inflammation in adults, as quantified by positron emission tomography (PET) with fluorine-2-deoxy-D-glucose (FDG) in individuals with increased psychosocial stress.
Primary Outcome
Change in arterial inflammation based on FDG PET - from initial imaging to repeat imaging.
Conditions Studied
Interventions
- BEHAVIORAL Stress Reduction
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2026-12-30 |
| Phase | NA |
What NCT04496947 shows while recruiting
NCT04496947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 786-participant average among 152 other Stress trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Stress appearing as the primary indexed condition, and to 1 intervention - of which Stress Reduction is the first listed.
NCT04496947 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04496947 about?
NCT04496947 is a clinical study titled "Pilot Study Evaluating the Impact of Stress Reduction on Atherosclerotic : Heart and Mind Study". The plot study aims to evaluate the effect of 8 weeks of stress reducing intervention on atherosclerotic plaque inflammation in adults, as quantified by positron emission tomography (PET) with fluorine-2-deoxy-D-glucose (FDG) in individuals with increased psychosocial stress.
What is the current status of trial NCT04496947?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2018-09-01. Estimated completion is 2026-12-30.
What conditions does trial NCT04496947 study?
This clinical trial studies the following conditions: Stress, Inflammation, Atherosclerosis.
What interventions are being tested in trial NCT04496947?
The interventions under investigation include: Stress Reduction (BEHAVIORAL).
Who is sponsoring clinical trial NCT04496947?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04496947 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04496947's enrollment target sits among peer trials
30 132nd of 152 higher than 16 of 152 other Stress trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stress trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mindfulness-Based Intervention With a Supplement for Stress-Related Problems in College Students Across Multiple Sites (4SITE)
RECRUITING · NA
-
Digital Intervention for Physical Activity
RECRUITING · NA
-
Cocooned Moms Study
RECRUITING · NA
-
Student Exercise and Sleep Timing Study - Part 2
RECRUITING · NA
-
Smartphone-based Cognitive Emotion Regulation Training for Unpaid Primary Caregivers of Persons With Alzheimer's Disease
RECRUITING · NA
-
ACT for HIV-Positive Men
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI